Safety and Efficacy of HSK3486 Compared to Propofol for Induction of General Anesthesia in Adults With Elective Surgery
NCT ID: NCT05486416
Last Updated: 2025-10-10
Study Results
Results available
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Clinical Phase
PHASE3
Total Enrollment
465 participants
Study Classification
INTERVENTIONAL
Study Start Date
2024-01-12
Study Completion Date
2024-07-23
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
To demonstrate HSK3486 0.4/0.2 mg/kg (0.4 mg/kg intravenous \[IV\] slow injection over 30 \[±5\] seconds for the first dose, an additional 0.2 mg/kg if needed) is non-inferior to Propofol 2.0/1.0 mg/kg (2.0 mg/kg IV slow injection over 30 \[±5\] seconds for first dose, an additional 1.0 mg/kg if needed) in success of induction of general anesthesia in adults undergoing elective surgery.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy and Safety of HSK3486 Compared to Propofol for Adults Undergoing Elective Surgery With General Anesthesia
NCT05478174
General Anesthesia
COMPLETED
PHASE3
Efficacy and Safety of HSK3486 Compared to Propofol in Induction of General Anesthesia in Adults Having Elective Surgery
NCT04711837
Anesthesia
COMPLETED
PHASE3
A Study to Evaluate the Efficacy and Safety of HSK3486 in the Induction of General Anesthesia
NCT04511728
Induction and Maintenance of General Anesthesia
COMPLETED
PHASE3
A Clinical Trial Evaluating the Efficacy and Safety of HSK3486 Injectable Emulsion in Elective Surgery Patients
NCT04048811
Induction and Maintenance of General Anesthesia
COMPLETED
PHASE2
A Phase IIa Study Investigating the Tolerance, Efficacy and Safety of HSK3486
NCT03698617
Induction of General Anaesthesia
COMPLETED
PHASE2
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This is a global multicenter, randomized, double-blinded, propofol-controlled, phase 3 clinical study to evaluate the efficacy and safety of HSK3486 for induction of general anesthesia in adults undergoing elective surgery with endotracheal intubation.
After screening, eligible subjects will be randomized in a 2:1 ratio to receive either HSK3486 0.4/0.2 mg/kg (i.e., 0.4 mg/kg IV slow injection over 30 \[±5\] seconds followed by an additional 0.2 mg/kg dose over 10 \[±2\] seconds if needed) or propofol 2.0/1.0 mg/kg (i.e., 2.0 mg/kg IV slow injection over 30 \[±5\] seconds followed by an additional 1.0 mg/kg dose over 10 \[±2\]seconds if needed) in a blinded manner. Enrolled subjects will be stratified by American Society of Anesthesiologists Physical Status (ASA-PS; I-II and III-IV), age (\<65 and ≥65 years), and Body Mass Index (BMI \<35 and ≥35 kg/m2). Endotracheal intubation will be performed after adequate anesthetic induction (Modified Observer's Assessment of Awareness/Sedation \[MOAA/S\] ≤1) (Appendix 1) has been achieved and administration of neuromuscular blocking agent.
Before surgery, premedication is allowed except for sedative-hypnotic or analgesic drugs. Premedication should be recorded if used.
Prior to administration of the study drug in the operating room, the preoperative readiness of each subject will be confirmed. Oxygen will be supplied through a facemask (oxygen flow rate: ≥4 L/min) at least 2 minutes before study drug administration. Subsequently, the investigator can adjust the oxygen flow according to the specific situation of the subject and maintenance IV solution (normal saline \[NS\], lactated ringer's \[LR\], or 5% dextrose) will be administrated through IV infusion. Throughout the pre-induction and induction periods, a timing device must be used to allow accuracy and sequencing of necessary assessments.
After screening, eligible subjects will be randomized in a 2:1 ratio to receive either HSK3486 0.4/0.2 mg/kg (i.e., 0.4 mg/kg IV slow injection over 30 \[±5\] seconds followed by an additional 0.2 mg/kg dose over 10 \[±2\] seconds if needed) or propofol 2.0/1.0 mg/kg (i.e., 2.0 mg/kg IV slow injection over 30 \[±5\] seconds followed by an additional 1.0 mg/kg dose over 10 \[±2\]seconds if needed) in a blinded manner. Enrolled subjects will be stratified by American Society of Anesthesiologists Physical Status (ASA-PS; I-II and III-IV), age (\<65 and ≥65 years), and Body Mass Index (BMI \<35 and ≥35 kg/m2). Endotracheal intubation will be performed after adequate anesthetic induction (Modified Observer's Assessment of Awareness/Sedation \[MOAA/S\] ≤1) (Appendix 1) has been achieved and administration of neuromuscular blocking agent.
Before surgery, premedication is allowed except for sedative-hypnotic or analgesic drugs. Premedication should be recorded if used.
Prior to administration of the study drug in the operating room, the preoperative readiness of each subject will be confirmed. Oxygen will be supplied through a facemask (oxygen flow rate: ≥4 L/min) at least 2 minutes before study drug administration. Subsequently, the investigator can adjust the oxygen flow according to the specific situation of the subject and maintenance IV solution (normal saline \[NS\], lactated ringer's \[LR\], or 5% dextrose) will be administrated through IV infusion. Throughout the pre-induction and induction periods, a timing device must be used to allow accuracy and sequencing of necessary assessments.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
General Anesthesia
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Surgical pre-induction analgesia
Primary Study Purpose
TREATMENT
Blinding Strategy
SINGLE
Participants
Double blinded, 2:1 ratio of HSK3489 and Propofol respectively
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
HSK3486 for general anesthesia induction
HSK3486 for induction of general anesthesia
Group Type
EXPERIMENTAL
HSK3486
Intervention Type
DRUG
HSK3486 for induction of general anesthesia
Propofol for general anesthesia induction
Propofol for induction of general anesthesia
Group Type
ACTIVE_COMPARATOR
Propofol
Intervention Type
DRUG
Propofol for induction of general anesthesia
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
HSK3486
HSK3486 for induction of general anesthesia
Intervention Type
DRUG
Propofol
Propofol for induction of general anesthesia
Intervention Type
DRUG
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Diprivan
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subjects must satisfy all of the following criteria at the screening visit:
1. Subjects undergoing elective surgery (non-emergency, non-cardiothoracic, and non-intracranial surgery anticipated to last at least 1 hour) requiring endotracheal intubation and inhalation general anesthesia during the maintenance period. Duration of surgery is defined as time from study drug administration to time of transfer from operating room to recovery room or PACU.
2. Males or females, aged ≥18 years old, with ASA PS I to IV (Appendix 6). For ASA-PS IV subjects, clinical status must be optimized at time of preoperative anesthesia evaluation per judgement of the anesthesiologist.
3. BMI ≥18 kg/m2.
4. Vital signs at screening: RR ≥10 and ≤24 breaths/min; SpO2 ≥92% in ambient air; SBP ≥90 and ≤160 mmHg; DBP ≥55 and ≤ 100 mmHg; HR ≥55 (or ≥50 if subjects are on beta blockers) and ≤100 beats/min.
5. For all women of childbearing potential, negative serum pregnancy test within the screening period and negative urine pregnancy test at baseline (Day 1). Additionally, women of childbearing potential\* and male subjects with female partners of childbearing potential must agree to use contraception as defined in 7.3.4 from the time of consent until 30 days post study drug administration.
6. For subjects with known hypothyroidism and/or on thyroid-hormone replacement treatment (i.e., thyroxine), or subjects suspected to have thyroid dysfunction based on clinical laboratory and physical exam, a TSH must drawn and be within normal levels.
7. Capable of understanding the procedures and methods of this study, willing to sign an Informed Consent Form (ICF), and able to complete this study in strict compliance with the study protocol.
8. Willing to comply with the site's COVID guidelines and testing requirements as applicable.
9. Patients with psychiatric/mental disorders must be considered stable on treatment (e.g., SSRIs, SNRIs, TCAs, MAOIs, psychotherapy) per investigator judgement, and no hospitalizations and urgent care due to the underlying psychiatric pathology for at least 12 months.
* Women are considered of childbearing potential until becoming post-menopausal, unless she had a documented hysterectomy or bilateral oophorectomy / salpingo-oophorectomy. A woman is considered to be post-menopausal if she had no menses for at least 12 consecutive months (without an alternative medical cause).
1. Subjects undergoing elective surgery (non-emergency, non-cardiothoracic, and non-intracranial surgery anticipated to last at least 1 hour) requiring endotracheal intubation and inhalation general anesthesia during the maintenance period. Duration of surgery is defined as time from study drug administration to time of transfer from operating room to recovery room or PACU.
2. Males or females, aged ≥18 years old, with ASA PS I to IV (Appendix 6). For ASA-PS IV subjects, clinical status must be optimized at time of preoperative anesthesia evaluation per judgement of the anesthesiologist.
3. BMI ≥18 kg/m2.
4. Vital signs at screening: RR ≥10 and ≤24 breaths/min; SpO2 ≥92% in ambient air; SBP ≥90 and ≤160 mmHg; DBP ≥55 and ≤ 100 mmHg; HR ≥55 (or ≥50 if subjects are on beta blockers) and ≤100 beats/min.
5. For all women of childbearing potential, negative serum pregnancy test within the screening period and negative urine pregnancy test at baseline (Day 1). Additionally, women of childbearing potential\* and male subjects with female partners of childbearing potential must agree to use contraception as defined in 7.3.4 from the time of consent until 30 days post study drug administration.
6. For subjects with known hypothyroidism and/or on thyroid-hormone replacement treatment (i.e., thyroxine), or subjects suspected to have thyroid dysfunction based on clinical laboratory and physical exam, a TSH must drawn and be within normal levels.
7. Capable of understanding the procedures and methods of this study, willing to sign an Informed Consent Form (ICF), and able to complete this study in strict compliance with the study protocol.
8. Willing to comply with the site's COVID guidelines and testing requirements as applicable.
9. Patients with psychiatric/mental disorders must be considered stable on treatment (e.g., SSRIs, SNRIs, TCAs, MAOIs, psychotherapy) per investigator judgement, and no hospitalizations and urgent care due to the underlying psychiatric pathology for at least 12 months.
* Women are considered of childbearing potential until becoming post-menopausal, unless she had a documented hysterectomy or bilateral oophorectomy / salpingo-oophorectomy. A woman is considered to be post-menopausal if she had no menses for at least 12 consecutive months (without an alternative medical cause).
Exclusion Criteria
1. Contraindications to deep sedation/general anesthesia or a history of adverse reaction to sedation/general anesthesia.
2. Known to be allergic to eggs, soy products, opioids and their antidotes, or propofol; subjects having contraindications to propofol, opioids, and their antidotes. In cases where the only previous reaction to opioids was itching or nausea, subjects need not be excluded if the investigator believes the subject is not truly allergic to opioids.
3. Medical condition or evidence of increased sedation/general anesthesia risk as follows:
1. Cardiovascular disorder: uncontrolled hypertension (SBP \>160 mmHg and/or DBP \>100 mmHg) with or without antihypertensive therapy (antihypertensive therapy should be stable for 1 month prior to screening), serious arrhythmia (including the subjects with implanted pace makers), unstable heart failure, Adams-Stokes syndrome (i.e., syncope or near-syncope due to cardiac arrythmia), unstable angina, myocardial infarction occurring within 6 months prior to screening, history of tachycardia/bradycardia requiring medications, third degree atrioventricular block or QT interval corrected for HR using Fridericia's formula (QTcF) ≥450 ms for males and ≥470 ms for females.
2. History of severe obstructive lung disease (i.e., forced expiratory volume in 1 second \[FEV1\] \<50% predicted), history of bronchospasm requiring treatment in a hospital emergency room or hospitalization occurring within 3 months prior to screening, developing acute respiratory tract infection within 2 weeks prior to baseline (such as symptoms of fever, shortness of breath, wheezing, nasal congestion, and cough).
3. Cerebrovascular disease: subject with a history of serious craniocerebral injury, convulsion, seizure disorder, intracranial hypertension, cerebral aneurysm, or stroke.
4. Patients with psychiatric/mental disorders who have not been on a stable treatment regimen (e.g., SSRIs, SNRIs, TCAs, MAOIs, psychotherapy) per investigator judgement, for at least 12 months or who have been hospitalized or had emergent/urgent care due to the underlying psychiatric pathology within the last 12 months.
5. Uncontrolled clinically significant conditions of liver (e.g., severe hepatic insufficiency defined as Childs-Pugh class C), kidney, gastrointestinal tract, blood system, nervous system, or metabolic system diseases, judged by the investigator to be unsuitable for involvement in the study.
6. History of uncontrolled diabetes in the opinion of the investigator.
7. History of alcohol abuse within 3 months prior to screening, where alcohol abuse refers to daily alcohol drinking \>2 units of alcohol (1 unit = 360 mL of beer or 45 mL of spirit with a strength of 40% or 150 mL of wine).
8. History of drug abuse that, in the opinion of the investigator, may confound the interpretation of safety or efficacy in a study subject.
9. For subjects with known hypothyroidism and/or on thyroid-hormone replacement treatment (i.e., thyroxine), or subjects suspected to have thyroid dysfunction based on clinical laboratory and physical exam who has a TSH value outside the normal range.
4. Management risks of respiratory tract and judged by the investigator to be unsuitable for inclusion in the study as follows:
1. Asthma must be stable: stable doses of asthma medications for the past 6 months, no requirement for rescue inhalers or oral steroids within past 6 months, not evaluated in emergency department, urgent care, or hospitalized for an asthma attack within past 1 year.
2. History (or family history) of malignant hyperthermia.
3. Any previous failure of tracheal intubation.
4. Judged to have a difficult airway for endotracheal intubation in the opinion of the Investigator based on parameters such as modified Mallampati score (Grade III or IV \[Appendix 7\]), neck mobility, short thyromental distance, and/or history of difficult intubation).
5. Any medication that has the potential to interact synergistically with propofol or HSK3486, including but not limited to all sedatives and hypnotics (e.g., benzodiazepines and opioids), taken within 5 half-lives prior to Day 1.
6. Laboratory parameters measured at screening with the following levels:
1. Neutrophil count ≤1.5 x 109/L
2. Platelet count \<80 x 109/L
3. Hemoglobin \<90 g/L (without blood transfusion within 14 days)
4. Alanine transaminase and/or aspartate transaminase ≥2.0 x upper limit of normal (ULN)
5. Total bilirubin ≥2.0 x ULN
6. Severe renal impairment defined by creatinine clearance (CrCl) ≤30 mL/min
7. Female subjects with a positive pregnancy test at screening (serum) or baseline (urine); lactating subjects; any subject planning to get pregnant within 1 month after the study (including the male subject's partner).
8. Judged by the investigator to have any other factors that make the subject unsuitable for participation in the study.
2. Known to be allergic to eggs, soy products, opioids and their antidotes, or propofol; subjects having contraindications to propofol, opioids, and their antidotes. In cases where the only previous reaction to opioids was itching or nausea, subjects need not be excluded if the investigator believes the subject is not truly allergic to opioids.
3. Medical condition or evidence of increased sedation/general anesthesia risk as follows:
1. Cardiovascular disorder: uncontrolled hypertension (SBP \>160 mmHg and/or DBP \>100 mmHg) with or without antihypertensive therapy (antihypertensive therapy should be stable for 1 month prior to screening), serious arrhythmia (including the subjects with implanted pace makers), unstable heart failure, Adams-Stokes syndrome (i.e., syncope or near-syncope due to cardiac arrythmia), unstable angina, myocardial infarction occurring within 6 months prior to screening, history of tachycardia/bradycardia requiring medications, third degree atrioventricular block or QT interval corrected for HR using Fridericia's formula (QTcF) ≥450 ms for males and ≥470 ms for females.
2. History of severe obstructive lung disease (i.e., forced expiratory volume in 1 second \[FEV1\] \<50% predicted), history of bronchospasm requiring treatment in a hospital emergency room or hospitalization occurring within 3 months prior to screening, developing acute respiratory tract infection within 2 weeks prior to baseline (such as symptoms of fever, shortness of breath, wheezing, nasal congestion, and cough).
3. Cerebrovascular disease: subject with a history of serious craniocerebral injury, convulsion, seizure disorder, intracranial hypertension, cerebral aneurysm, or stroke.
4. Patients with psychiatric/mental disorders who have not been on a stable treatment regimen (e.g., SSRIs, SNRIs, TCAs, MAOIs, psychotherapy) per investigator judgement, for at least 12 months or who have been hospitalized or had emergent/urgent care due to the underlying psychiatric pathology within the last 12 months.
5. Uncontrolled clinically significant conditions of liver (e.g., severe hepatic insufficiency defined as Childs-Pugh class C), kidney, gastrointestinal tract, blood system, nervous system, or metabolic system diseases, judged by the investigator to be unsuitable for involvement in the study.
6. History of uncontrolled diabetes in the opinion of the investigator.
7. History of alcohol abuse within 3 months prior to screening, where alcohol abuse refers to daily alcohol drinking \>2 units of alcohol (1 unit = 360 mL of beer or 45 mL of spirit with a strength of 40% or 150 mL of wine).
8. History of drug abuse that, in the opinion of the investigator, may confound the interpretation of safety or efficacy in a study subject.
9. For subjects with known hypothyroidism and/or on thyroid-hormone replacement treatment (i.e., thyroxine), or subjects suspected to have thyroid dysfunction based on clinical laboratory and physical exam who has a TSH value outside the normal range.
4. Management risks of respiratory tract and judged by the investigator to be unsuitable for inclusion in the study as follows:
1. Asthma must be stable: stable doses of asthma medications for the past 6 months, no requirement for rescue inhalers or oral steroids within past 6 months, not evaluated in emergency department, urgent care, or hospitalized for an asthma attack within past 1 year.
2. History (or family history) of malignant hyperthermia.
3. Any previous failure of tracheal intubation.
4. Judged to have a difficult airway for endotracheal intubation in the opinion of the Investigator based on parameters such as modified Mallampati score (Grade III or IV \[Appendix 7\]), neck mobility, short thyromental distance, and/or history of difficult intubation).
5. Any medication that has the potential to interact synergistically with propofol or HSK3486, including but not limited to all sedatives and hypnotics (e.g., benzodiazepines and opioids), taken within 5 half-lives prior to Day 1.
6. Laboratory parameters measured at screening with the following levels:
1. Neutrophil count ≤1.5 x 109/L
2. Platelet count \<80 x 109/L
3. Hemoglobin \<90 g/L (without blood transfusion within 14 days)
4. Alanine transaminase and/or aspartate transaminase ≥2.0 x upper limit of normal (ULN)
5. Total bilirubin ≥2.0 x ULN
6. Severe renal impairment defined by creatinine clearance (CrCl) ≤30 mL/min
7. Female subjects with a positive pregnancy test at screening (serum) or baseline (urine); lactating subjects; any subject planning to get pregnant within 1 month after the study (including the male subject's partner).
8. Judged by the investigator to have any other factors that make the subject unsuitable for participation in the study.
Minimum Eligible Age
18 Years
Maximum Eligible Age
99 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Haisco-USA Pharmaceuticals, Inc.
INDUSTRY
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
North Alabama Medical Center
Florence, Alabama, United States
Site Status
Helen Keller Hospital
Sheffield, Alabama, United States
Site Status
University of Miami Hospital
Miami, Florida, United States
Site Status
Gulfcoast Research Institute
Sarasota, Florida, United States
Site Status
Phoenix Clinical Research, LLC
Tamarac, Florida, United States
Site Status
ForCare Clinical Research
Tampa, Florida, United States
Site Status
Atlanta Center for Medical Research
Atlanta, Georgia, United States
Site Status
EBGS Clinical Research Center
Snellville, Georgia, United States
Site Status
University of Iowa Hospitals and Clinics (Dept of Anesthesia)
Iowa City, Iowa, United States
Site Status
U of L Health, University of Louisville Hospital
Louisville, Kentucky, United States
Site Status
The Brigham and Women's Hospital
Boston, Massachusetts, United States
Site Status
Michigan Medicine
Ann Arbor, Michigan, United States
Site Status
M3-Emerging Medical Research, LLC
Durham, North Carolina, United States
Site Status
Duke University Medical Center (DUMC)
Durham, North Carolina, United States
Site Status
The Ohio State University Wexner Medical Center - University Hospital
Columbus, Ohio, United States
Site Status
First Surgical Hospital
Bellaire, Texas, United States
Site Status
Legent Orthopedic Hospital
Carrollton, Texas, United States
Site Status
The University of Texas MD Anderson Cancer Center
Houston, Texas, United States
Site Status
Memorial Hermann Village
Houston, Texas, United States
Site Status
Clinical Trials of Texas, LLC
San Antonio, Texas, United States
Site Status
Endeavor Clinical Trials, LLC
San Antonio, Texas, United States
Site Status
Uniwersytecki Szpital Kliniczny W Opolu
Opole, , Poland
Site Status
Państwowy Instytut Medyczny Mswia - Klinika Anestezjologii I Intensywnej Terapii
Warsaw, , Poland
Site Status
Spsk Nr 1 Im. Prof. S. Szyszko
Zabrze, , Poland
Site Status
Hospital Clinic De Barcelona
Barcelona, , Spain
Site Status
Hospital General Universitario De Ciudad Real
Ciudad Real, , Spain
Site Status
Universidad de Navarra - Clinica Universidad de Navarra en Pamplona
Pamplona, , Spain
Site Status
Hospital Clinico Universitario de Valencia (CHUV)
Valencia, , Spain
Site Status
Countries
Review the countries where the study has at least one active or historical site.
United States
Poland
Spain
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol and Statistical Analysis Plan: HSK3486-309 Protocol V9.0
Document Type: Statistical Analysis Plan: HSK3486-309 Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HSK3486-309
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
A Study Evaluating the Safety and Pharmacokinetics/Pharmacodynamics of HSK3486
NCT03745625
COMPLETED
PHASE1
Dose-Finding and Human Abuse Potential Study Of HSK3486 Injection In Nondependent, Recreational Central Nervous System Depressant Users
NCT05614544
COMPLETED
PHASE1
Efficacy and Safety Study of Two Propofol Formulations
NCT00506246
COMPLETED
PHASE3
Simultaneous Injection of Propofol and Rocuronium in Inducing General Anesthesia
NCT03270696
COMPLETED
NA
Comparison of Different Propofol Formulations
NCT01041872
COMPLETED
PHASE4
Phase III Clinical Trial Evaluating the Efficacy and Safety of Ciprofol Injection for the Induction of Sedation/Anesthesia in Subjects Undergoing Gynecological Outpatient Surgeries
NCT04958746
COMPLETED
PHASE3
Esketamine-propofol Versus Propofol for Flexible Bronchoscopy
NCT05643066
COMPLETED
PHASE4
Comparison Between Propofol and Inhalational Anaesthetic Agents on Cardiovascular Outcomes Following Cardiac Surgery
NCT04039854
UNKNOWN
PHASE4
ED90 of Fospropofol Disodium in Induction and Maintenance of Anesthesia
NCT06344325
COMPLETED
PHASE4
Effect Site Controlled, Reaction Time Safeguarded, Patient Maintained Sedation With Propofol in Healthy Volunteers
NCT00321360
COMPLETED
PHASE4
Application of the Propofol Precise Infusion Model
NCT05158426
COMPLETED
A Study to Evaluate the Differences in Pharmadynamics, Pharmacokinetics, and Safety Between Ciprofol and Propofol
NCT04294056
COMPLETED
PHASE1
Hemodynamics During Induction of General Anesthesia With High and Low Propofol Dose.
NCT03861364
COMPLETED
PHASE4
General Anesthetics in CAncer REsection Surgery (GA-CARES) Trial
NCT03034096
COMPLETED
PHASE4
Comparison of Etomidate Plus Propofol, Etomidate Alone on Induction of Anesthesia
NCT03820388
COMPLETED
PHASE4
Comparison of Different Propofol Formulations With or Without Remifentanil
NCT01592162
COMPLETED
PHASE4
Patient-controlled Sedation With Propofol Versus Anesthesiologist-administered Sedation for Orthopedic Surgery
NCT06451380
COMPLETED
NA
Comparative Clinical Study of Efficacy and Safety of Remimazolam and Propofol in Patients Undergoing Elective Surgery Under General Anaesthesia
NCT03669484
COMPLETED
PHASE3
Esketamine Anesthesia in Thoracic Surgery
NCT06310785
COMPLETED
NA
Effect of a Modified Propofol Preparation on Injection Pain During Induction of Anesthesia in Children
NCT00287560
COMPLETED
PHASE3
Bioequivalence Study of Propofol Medium and Long Chain Fat Emulsion Injection in Healthy Chinese Subjects
NCT07057609
COMPLETED
PHASE1
A Study to Evaluate the Accuracy of aTCI Model of Cipepofol in Patients With General Anesthesia During Elective Surgery
NCT06740201
RECRUITING
PHASE4
Propofol EC50 for Inducing Loss of Consciousness in General Combined Epidural Anesthesia
NCT05124704
COMPLETED
NA
A PK/PD Study of Fospropofol Disodium Compared With Propofol Injectable Emulsion
NCT01260142
COMPLETED
PHASE4
Use of a Modified Propofol Emulsion in Adults
NCT00690495
COMPLETED
PHASE3